Russell Frank Company’s Karyopharm Therapeutics KPTI Stock Holding History

Russell Frank Company’s Portfolio KPTI Stock Details KPTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-5	Closed	-$3K	–	3002
2014 Q4	$3K	Hold	5	–	–	﹤0.01%	2962
2014 Q3	$3K	Buy	+5	New	+$2.82K	﹤0.01%	2838
2014 Q2	–	Sell	-2,746	Closed	-$1.05M	–	2809
2014 Q1	$1.05M	Buy	+2,746	New	+$1.39M	﹤0.01%	2064

Other funds holding KPTI

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

SAM

Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCM

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Russell Frank Company's KPTI Position: Q1 2015 in Review

Russell Frank Company sold out of Karyopharm Therapeutics (KPTI) in Q1 2015, closing a stake of 5 shares — an estimated $3K sold.

Russell Frank Company first reported a position in KPTI in Q1 2014 and held it in 3 quarters. The position peaked at $1.05M in Q1 2014. 85 funds tracked by Wall St. Rank hold KPTI as of Q1 2015.

Russell Frank Company reported no remaining Karyopharm Therapeutics position as of Q1 2015 after selling out during the quarter.
Russell Frank Company sold 5 Karyopharm Therapeutics shares in Q1 2015, an estimated $3K.
Russell Frank Company first reported a position in Karyopharm Therapeutics in Q1 2014 and held it in 3 quarters.
Russell Frank Company's Karyopharm Therapeutics position peaked at $1.05M in Q1 2014.
85 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2015.

Based on Russell Frank Company's 13F filing for Q1 2015, filed 13 May 2015.